Solid Biosciences LLC (SLDB)

NASDAQ
Currency in USD
3.440
+0.560(+19.44%)
Closed
After Hours
3.490+0.050(+1.453%)
SLDB Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
Fair Value
Day's Range
3.2703.970
52 wk Range
2.88015.050
Key Statistics
Edit
Prev. Close
3.44
Open
3.63
Day's Range
3.27-3.97
52 wk Range
2.88-15.05
Volume
4.6M
Average Vol. (3m)
513.87K
1-Year Change
-55.78%
Book Value / Share
4.33
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SLDB Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
16.900
Upside
+391.28%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Solid Biosciences LLC Company Profile

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company’s lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich’s ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Solid Biosciences LLC SWOT Analysis


Financial Outlook
Cash runway into 2026 supports clinical progress, with analyst price targets ranging from $15 to $16, despite current market volatility
Expanding Horizons
FDA clearance for SGT-212 in Friedreich's ataxia marks significant pipeline expansion, addressing both neurologic and cardiac manifestations
DMD Breakthrough
SGT-003 for Duchenne muscular dystrophy enters Phase 1/2 trials, promising potential superiority over first-generation therapies
Gene Therapy Pionee
Solid Biosciences leads in AAV-based gene therapies for DMD and FA, with innovative approaches to transgene optimization and capsid design
Read full SWOT analysis

Compare SLDB to Peers and Sector

Metrics to compare
SLDB
Peers
Sector
Relationship
P/E Ratio
−1.3x−5.8x−0.6x
PEG Ratio
−0.030.040.00
Price / Book
0.8x2.3x2.6x
Price / LTM Sales
-31.9x3.1x
Upside (Analyst Target)
365.1%142.1%48.7%
Fair Value Upside
Unlock6.1%7.7%Unlock

Analyst Ratings

12 Buy
0 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 16.900
(+391.28% Upside)

Earnings

Latest Release
May 11, 2023
EPS / Forecast
-1.54 / -1.64
Revenue / Forecast
-- / 1.47M
EPS Revisions
Last 90 days

People Also Watch

27.71
CSTL
+0.40%
35.73
LEGN
+0.99%
41.07
IONQ
+1.23%
11.59
ARQT
-0.17%
5.830
QBTS
+0.34%

FAQ

What Is the Solid Biosciences (SLDB) Stock Price Today?

The Solid Biosciences stock price today is 3.44

What Stock Exchange Does Solid Biosciences Trade On?

Solid Biosciences is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Solid Biosciences?

The stock symbol for Solid Biosciences is "SLDB."

What Is the Solid Biosciences Market Cap?

As of today, Solid Biosciences market cap is 137.44M.

What is Solid Biosciences Earnings Per Share?

The Solid Biosciences EPS is -2.91.

From a Technical Analysis Perspective, Is SLDB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.